A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Vincenzo Spagnuolo,1,2 Laura Galli,2 Andrea Poli,2 Alba Bigoloni,2 Luca Fumagalli,2 Nicola Gianotti,2 Silvia Nozza,2 Davide Ferrari,3 Massimo Locatelli,3 Adriano Lazzarin,2 Antonella Castagna1,2 1Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy; 2Clinic of Infectio...

Full description

Bibliographic Details
Main Authors: Spagnuolo V, Galli L, Poli A, Bigoloni A, Fumagalli L, Gianotti N, Nozza S, Ferrari D, Locatelli M, Lazzarin A, Castagna A
Format: Article
Language:English
Published: Dove Medical Press 2019-01-01
Series:Drug Design, Development and Therapy
Subjects:
HIV
atazanavir
dolutegravir
virologic failure
Online Access:https://www.dovepress.com/a-nucleoside-sparing-regimen-of-dolutegravir-plus-ritonavir-boosted-at-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/a-nucleoside-sparing-regimen-of-dolutegravir-plus-ritonavir-boosted-at-peer-reviewed-article-DDDT

Similar Items